Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The Company provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The Company operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.

Employees

Sector

Pharmaceuticals

Calendar

Nov. 12 Earnings release - Q2 2027

More about the company

Quotes

Date	Price	Change	Volume
26-10-29	¥7,350.00	+0.55%	190,600
26-10-28	¥7,310.00	+3.69%	260,900
26-10-27	¥7,050.00	+8.63%	247,300
26-10-26	¥6,490.00	+0.46%	130,600
26-10-23	¥6,460.00	+1.41%	223,200

Delayed Quote Japan Exchange

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Cuorips Inc.

Company calendar

Delayed Japan Exchange 02:30:00 2026-10-29 am EDT			5-day change	1st Jan Change
7,350.00 ^JPY	+0.55%		+15.38%	+21.89%

Sep. 27	Cuorips Inc. announced that it has received ¥2.9999677 billion in funding from JIC Venture Growth Investments Co., Ltd.	CI
Sep. 11	Cuorips Inc. announced that it expects to receive ¥2.9999677 billion in funding from JIC Venture Growth Investments Co., Ltd.	CI

Market Cap	64.92B 410M 368M 340M 308M 576M 39.08B 583M 4.07B 1.62B 20.45B 1.54B 1.51B	P/E 2025	-103x	P/E 2026	-56.3x
Enterprise Value	61.02B 386M 346M 320M 290M 541M 36.73B 548M 3.82B 1.52B 19.22B 1.45B 1.42B	EV / Sales 2025	356x	EV / Sales 2026	255x
Free-Float	77.06%	Yield 2025 *	-	Yield 2026	-

Sep. 27	Cuorips Inc. announced that it has received ¥2.9999677 billion in funding from JIC Venture Growth Investments Co., Ltd.	CI
Sep. 11	Cuorips Inc. announced that it expects to receive ¥2.9999677 billion in funding from JIC Venture Growth Investments Co., Ltd.	CI
Feb. 19	Japan Panel Clears First iPS Cell Therapies for Conditional Sale	MT
Feb. 19	Japanese government panel endorses Sumitomo Pharma's iPS-derived treatment for Parkinson's	RE
Feb. 19	Japan government panel endorses Sumitomo Pharma's iPS-derived treatment for Parkinson's, newspaper says	RE
Feb. 03	Takeda, Kyoto University to End Decade-Long iPS Research Tie-Up	MT
24-09-22	Cuorips Inc.(TSE:4894) added to S&P Global BMI Index	CI
23-12-22	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023.	CI
23-09-23	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 24-SEP-2023.	CI
23-06-27	Cuorips Inc. has completed an IPO in the amount of Â¥3.432 billion.	CI

Feb. 19	UPDATE2: Japan gov't panel approves 2 iPS-derived drugs in global first	AQ
Feb. 19	UPDATE1: Japan gov't panel approves 2 iPS-derived drugs in global first	AQ
Feb. 19	Japan gov't panel approves 2 iPS-derived drugs in global first	AQ

Cuorips Inc. Stock

Stocks

4894

JP3266030000

Pharmaceuticals

Valuation: Cuorips Inc.

Chart: Cuorips Inc.

Latest news: Cuorips Inc.

Press Releases: Cuorips Inc.

News in other languages: Cuorips Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Cuorips Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 day	+0.55%
1 week	+15.38%
Current month	+10.69%
1 month	+30.32%
3 months	+73.55%
6 months	+10.36%
Current year	+21.89%

1 week	6,050	7,460
1 month	6,020	7,460
Current year	3,610	12,400
1 year	3,610	12,400
3 years	1,534	12,400
5 years	1,287	12,400
10 years	1,287	12,400

Manager	Title	Age	Since
Takayuki Kusanagi CEO	Chief Executive Officer	67	2020-05-31
Tanamura Tadayuki ADM	Chief Administrative Officer	45	2024-05-31
Yoshiki Sawa CTO	Chief Tech/Sci/R&D Officer	71	2021-07-31

Director	Title	Age	Since
Takayuki Kusanagi BRD	Director/Board Member	67	2020-07-31
Yoshiki Sawa BRD	Director/Board Member	71	2021-07-31
Tanamura Tadayuki BRD	Director/Board Member	45	2024-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CUORIPS INC.	+0.55%	+15.38%	+15.38%	+371.15%	410M
ELI LILLY AND COMPANY	+0.50%	+1.38%	+57.09%	+129.96%	1,148B
JOHNSON & JOHNSON	+0.86%	+5.14%	+45.00%	+86.15%	652B
ABBVIE INC.	-0.14%	+0.42%	+25.69%	+105.85%	505B
ROCHE HOLDING AG	+0.34%	+1.73%	+52.74%	+67.74%	384B
MERCK & CO., INC.	-0.63%	-5.97%	+61.93%	+37.06%	348B
NOVARTIS AG	+1.39%	+1.84%	+30.70%	+54.27%	294B
ASTRAZENECA PLC	+0.94%	+1.19%	+2.89%	+26.08%	264B
AMGEN INC.	+0.87%	+3.08%	+54.69%	+72.74%	244B
GILEAD SCIENCES, INC.	+0.08%	+3.67%	+35.05%	+107.78%	197B
Average	+0.47%	+1.69%	+38.12%	+105.88%	403.76B
Weighted average by Cap.	+0.46%	+1.50%	+44.52%	+89.13%

	2025	2026
Net sales	175M 1.11M 992K 917K 831K 1.55M 105M 1.57M 10.97M 4.37M 55.12M 4.15M 4.06M	212M 1.34M 1.2M 1.11M 1.01M 1.88M 128M 1.9M 13.29M 5.29M 66.78M 5.03M 4.92M
Net income	-644M -4.07M -3.65M -3.38M -3.06M -5.71M -388M -5.78M -40.37M -16.08M -203M -15.27M -14.95M	-1.02B -6.46M -5.8M -5.36M -4.85M -9.07M -615M -9.18M -64.06M -25.52M -322M -24.24M -23.73M
Net Debt	-4.79B -30.29M -27.18M -25.13M -22.76M -42.52M -2.89B -43.03M -300M -120M -1.51B -114M -111M	-3.9B -24.64M -22.11M -20.44M -18.51M -34.59M -2.35B -35.01M -244M -97.35M -1.23B -92.48M -90.53M